Showing results (31-40 of 466) with videos related to

Sort By:
Pageof 47
Journal De Radiologie|August 1, 1979
[Lymph node involvement of squamous cell carcinoma of the oesophagus. Contribution of thoracic radiograph (author's transl)]J Stines, F Boman, P Bey, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|July 16, 2002
[Conformal radiotherapy in prostate cancer: for whom and how?]P Bey, V Beckendorf, P Aletti, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 1995
Detection of errors in individual patients in radiotherapy by systematic in vivo dosimetryA Noel, P Aletti, P Bey, et al.
Annales D'Oto-Laryngologie Et De Chirurgie Cervico Faciale : Bulletin De La Societe D'Oto-Laryngologie Des Hopitaux De Paris|January 1, 1981
[Carcinoma of a nasopharynx. Apropos of 42 cases treated between 1968 and 1977]P Bey, B Gueddari, L Malissard, et al.
Biochemical Pharmacology|December 1, 1982
alpha-Monofluoromethyl and alpha-difluoromethyl putrescine as ornithine decarboxylase inhibitors: in vitro and in vivo biochemical propertiesC Danzin, P Bey, D Schirlin, et al.
Bulletin Du Cancer|March 6, 1999
[Standards, options and recommendations (SOR) for diagnosis, treatment and follow-up of osteosarcoma. Groupe de travail SOR]T Philip, J Y Blay, M Brunat-Mentigny, et al.
Journal of Medicinal Chemistry|November 1, 1983
alpha-(Fluoromethyl)dehydroornithine and alpha-(fluoromethyl)dehydroputrescine analogues as irreversible inhibitors of ornithine decarboxylaseP Bey, F Gerhart, V Van Dorsselaer, et al.
Bulletin Du Cancer|May 26, 1999
[Standards, options and recommendations (SOR) for clinical care of malignant thymoma. Groupe de Travail SOR]P Ruffié, G Gory-Delabaere, B Fervers, et al.
Journal of Neurochemistry|August 1, 1984
MDL 72145, an enzyme-activated irreversible inhibitor with selectivity for monoamine oxidase type BM Zreika, I A McDonald, P Bey, et al.
Bulletin Du Cancer|January 1, 1989
[Immediate hematological toxicity during combination chemotherapy-radiotherapy of Hodgkin's disease]D Peiffert, P Bey, P Lederlin, et al.
Pageof 47